Cardinal Health (CAH) Q4 FY26 earnings call: guidance and Q&A

Can you elaborate on the drivers of strong Pharma and Specialty Solutions AOI growth in Q4 and how that momentum translates into the 8-11% FY27 guidance?

Management attributed Q4 strength to strong demand across key product categories, largest customers, strong specialty growth at higher margins, and positive generics program performance. For FY27, they expect these trends to continue, but without the 'outsized' demand experienced periodically in FY26. M&A concluded in FY26 will contribute 2-3 percentage points to FY27 profit growth.

“From a guidance perspective, we expect all of those to continue into our fiscal year '27. Now you heard us call out the broader context from a guidance for the year. I do want to point out that, ofcourse, we are not assuming outsized demand, which, as you know, we did experience a couple of times over the course of fiscal year '26.”

asked by Erin Wilson Wright · answered by Aaron Alt

How will specialty growth transition in FY27, focusing more on services as initial integration waves conclude?

Specialty growth was very solid in FY26 (over 25%), driven by distribution and M&A. For FY27, similar trends are expected but not to the same extent. Biopharma Solutions is on track for 20%+ growth towards a $1 billion target by FY28. The strategy connects different business parts to create growth and better services for customers and patients.

“Overall, we had a very solid specialty growth in fiscal '26, about -- actually, over 25% growth overall, and that was certainly strong specialty distribution, but also some contributions from the M&A that Aaron highlighted. So we have a really strong momentum there as well as the broader segment.”

asked by Elizabeth Anderson · answered by Jason Hollar

What other regulatory changes are you watching besides IRA, and what is the potential impact of 340B changes on hospital customers and your volume/opportunity?

Management is tightly plugged into customers, manufacturers, and administration, focusing on access and affordability. They believe if affordability is prioritized, it drives volume, which is key to their business. They adapt to changes like IRA and 340B, working with customers to understand logistics. They don't see their role changing and expect compensation to remain stable. They acknowledge customer impact (e.g., hospitals with 340B) is likely greater than their own, tracking potential impacts on procedures and patient access.

“If affordability continues to be the priority and there are actions to make health care more affordable, then that drives volume, and that really is the lifeblood of our business. It's the key driver of what we need to be able to invest into the business. So we absolutely support the administration's efforts to that improved access and affordability.”

asked by Lisa Gill · answered by Jason Hollar

Compare FY27 investment priorities to FY26, highlighting what's continued or incremental. Is capacity building for existing customers or potential new wins?

Investment priorities remain consistent, focusing on faster-growing, more specialized, and fragmented market areas like specialty and at-Home. Examples include MSOs (GI, oncology, urology) and at-Home acquisitions (Strive, AdaptHealth Diabetes). Organic investments are spread across businesses. Capacity building is proactive, addressing bottlenecks like refrigeration/freezing and incorporating automation to create capacity and lower costs per order, ensuring service levels for planned growth rather than speculative new wins.

“So I think we're in the very early innings of that scaling of these capabilities. So let's just kind of look at a couple of the big ones. Within MSOs, we certainly invested heavily in autoimmune, namely within GI, oncology and urology.”

asked by Eric Percher · answered by Jason Hollar

Quantify Pharma revenue softness due to brand-to-generic conversion and EBIT acceleration from generics in Q4, and how this impacts FY27.

Generics were a positive contributor to Q4 and FY26 results, with further benefit from brand-to-generic conversion. This profit benefit is expected to continue in FY27. While GLP-1 growth and IRA WAC changes each had an approximate 500 basis points offsetting impact on revenue, the brand-to-generic conversion impact on revenue softness was well below 500 basis points. The profit from generics drops directly to the bottom line.

“You are right to call out that generics was a positive part of our delivery certainly for the quarter and for the year as well. Naturally, we prefer the profitability that comes with a generic conversion. And as we called out in our prepared remarks, we did see some further benefit in the quarter from that.”

asked by Allen Lutz · answered by Aaron Alt

Clarify the renewal of the largest customer (assuming CVS) and discuss how disaggregation of services due to reform initiatives might create opportunities or recontracting needs.

The largest customer renewal mentioned was for the GMPD segment, not CVS. Cardinal Health has a broad, long-standing strategic relationship with CVS across distribution, Red Oak, Averon, and IQ purchasing. Management emphasizes their role in physically moving product and taking on ownership/risk, deploying billions in capital. They believe their value proposition ensures they remain an essential partner even as models evolve, supporting customers who bear more risk and return.

“First of all, I'd be really clear. We were on the GMPD section when I highlighted the renewal of our largest customer. So George, you might have been multitasking. You heard those words and just jumped on it. So yes, that was GMPD.”

asked by George Hill · answered by Jason Hollar

Provide more information on input cost pressures in GMPD and update on where GMPD fits within the overall strategy given its improved profitability.

Input cost pressures are primarily from oil and petroleum products (diesel fuel) and oil-based commodities like polyethylene, polypropylene, and polyvinyl. While impactful, these are more manageable than in the past due to flexible commercial environments. A tariff tailwind is expected to largely offset these in FY27, but protracted elevation could push GMPD profit to the lower end of guidance. GMPD's strategic fit remains strong, with continued focus on the improvement plan, growing Cardinal Health brand volume, and simplification actions, while delivering improved service and quality.

“As it relates to the commodity costs that we're always tracking very closely and that where we see some pressure today, think just oil and petroleum types of products, so diesel fuel being something that impacts our distribution, logistics, costs, and the oil-based come up, these things like polyethylene, polypropylene, polyvinyl, these types of products, but it goes broader than that as well, some resins.”

asked by Lucas Romanski · answered by Jason Hollar